Antibody Drug Conjugate Market Opportunity Analysis

Ever since the first attempt in the 1980's to use antibody-based drugs as therapeutic agents, the application and use of monoclonal antibody-drug conjugates has evolved in several ways. The major advantage of using Antibody Drug Conjugates (ADC) is that it brings together the best characteristics of both antibodies and the cytotoxic potential of chemotherapy. This offers significant opportunity for the future in terms of targeted accumulation of drug in the tumor cell or tissue.

The Antibody Drug Conjugates has evolved into a special therapeutic class of drugs which can now save patients who suffer from those diseases for which there was no adequate treatment previously. However, one of the major challenges is that the treatment with antibody drugs is highly expensive. From a medical economic perspective, it is most likely that the cost versus value ratio would weigh very high in the future. In order to improve this, it is important that the reliable efficiency of the drugs be proved. Hence, the current market is witnessing an increasing number of pharma companies increasingly focusing their efforts into this field.

Download Report:

https://www.kuickresearch.com/report-Antibody-Drug-Conjugate-Market-Opportunity-Analysis.php

With the approvals of brentuximab vedotin(Adcetris) and ado-trastuzumab emtansine (Kadcyla), and more than 100 ADCs in the clinical trial pipeline, the market for this therapeutic class is expected to grow significantly in the future years. It is most likely that the global ADC market would grow at a CAGR of more than 40% to reach USD 6.8 billion by 2020. The other major drivers of the ADC market include the technological advances made in the linker technology and patent fencing. Also, with the entry of large number of companies into this segment, it is likely that competition levels would increase significantly, which would in turn lead to high demand and market value in the years to come.

The Antibody Drug Conjugates market will definitely witness an increase in the partnership and collaborative agreements to develop these drugs. It has been observed that the process of drug development is highly correlated to basic research in Biology and Medicine. Specifically, the details about target molecules and their functions along with their involvement in pathology generally stem from basic research which is conducted in universities and public research institutes. The recent years have thus witnessed a growing relationship between the pharma companies and the academic institutions. Majority of the pharmaceutical companies across the globe have been reducing the size of their departments for basic research. Instead they have started to depend heavily on venture companies and universities, which act as the major source of knowledge.

“Antibody Drug Conjugate Market Opportunity Analysis” Report Highlights:

* Global ADC Market Insight
* ADC Patent Analysis
* Orphan Status & ADC
* Favorable Market Drivers & Key Issues to be Discussed
* ADC Clinical Trial Insight by Phase & Target Indications
* ADC Profiles in Report: 201
* Majority of ADC in Preclinical Phase: 83
* Marketed ADC Clinical Profiles

For Report Sample Contact: neeraj@kuickresearch.com or

visit: https://www.kuickresearch.com

Recent Publications:

* Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022
* Global CAR T Cell Therapy Market & Clinical Trials Insight 2022
* Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023
* Global Microcapsules Drug Delivery Market Opportunity Outlook 2022
* Global Controlled Drug Delivery Market & Clinical Trial Outlook 2022
* Global Cancer Antibody Drug Conjugates Market & Pipeline Insight 2022
* Global B Cell Lymphoma Market & Clinical Pipeline Insight 2022

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.